Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the
safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor
activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation